Christopher Kimball

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Cooley advised PruVen Capital, an independent venture capital firm whose investors are exclusively global leaders in financial services and insurance, on the close of its oversubscribed $378.5 million second fund.

Cooley advised Grafana Labs, the company behind ubiquitous, open and composable operational dashboards, on the successful completion of its approximately $270 million primary and secondary transaction.

Cooley advised DEFCON AI, an insights company that’s building a next-generation modeling, simulation and analysis tool set for the modern military environment, on its $44 million in Seed financing.

Cooley advised Founders Fund, a venture capital firm investing in smart people solving difficult problems, as a co-lead investor in Anduril Industries’ $1.5 billion Series F funding round, which increased Anduril’s valuation to $14 billion.